Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00399035
Status:
COMPLETED
Last Update Posted:
2016-12-28
First Post:
2006-11-13
Brief Title:
Cediranib AZD2171 RECENTIN in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomised Double-blind Phase III Study to Compare the Efficacy and Safety of Cediranib AZD2171 RECENTIN When Added to 5 Fluorouracil Leucovorin and Oxaliplatin FOLFOX or Capecitabine and Oxaliplatin XELOX With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HORIZON II
Brief Summary:
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HORIZON II | None | None | None |
| EUDRACT No 2006-001194-14 | None | None | None |